Recombinant Hepatitis B Vaccine (Hansenula)

This product is made by purifying the hepatitis B virus surface antigen (HBsAg) expressed by recombinant Hansen yeast and adsorbing it with aluminum adjuvant. It is a milky white suspension liquid that can be separated by precipitation and is easy to shake. The main ingredient is hepatitis B surface antigen; the auxiliary materials include aluminum hydroxide and sodium chloride.

After vaccination, this vaccine can stimulate the body to produce immunity against hepatitis B virus and is used to prevent hepatitis B.

1. Common adverse reactions: local pain, redness, swelling or moderate to low fever at the injection site. Generally, no special treatment is required and the symptoms can be relieved on their own. If necessary, symptomatic treatment can be given. 2. Rare adverse reactions: anaphylactic shock, demyelination, allergic rash, thrombocytopenic purpura, nervous system diseases, acute glomerulonephritis and liver and kidney diseases. The incidence rate is 1/600,000.

It is forbidden to use the product if you have fever, acute or chronic serious illness or are allergic to yeast ingredients.

Precautions for children: Precautions for pregnancy and lactation:

Store and transport at 2-8°C away from light.

10μg/0.5ml

Vials: 36 months, ampoules: 24 months

Aimei Chengxin Biopharmaceutical Co., Ltd.

• Founded in:

  1993-09-20

• Address:

  1-3F, No. 35-4, Wanda Road, Dalian Economic and Technological Development Zone, China (Liaoning) Pilot Free Trade Zone

• Tax NO.:

  91210213241314449J

• Registered Funds:

  250 million yuan

• Website:

  Log in to view

• Email:

  Log in to view